ArticleBiosensors2026
Inkjet-Printed Electrode Enable Portable Electrochemical Immunosensing of Tau-441 for Early Alzheimer's Screening.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Early diagnosis of Alzheimer's disease represents a critical clinical challenge, and the high-sensitive biomarkers measurement holds great potential for enabling early identification and intervention. This study proposes an electrochemical immunosensing strategy based on inkjet printing for the quantitative detection of Tau-441. Conductive patterns were formed by inkjet printing, followed by surface functionalization with gold nanoparticles to immobilize highly specific anti-Tau-441. This process created a stable and high affinity immunorecognition interface that enhances electron transfer and signal amplification. Furthermore, we developed and integrated a low-power portable detection platform to achieve a rapid detection process encompassing sample loading, signal acquisition, and on-device readout. The method shows a linear response from 50 fg/mL to 10 ng/mL and a limit of detection of 16 fg/mL (S/N = 3), with high specificity and good reproducibility. By combining scalable inkjet fabrication with a self-contained handheld reader, this method shortens the path from sample to result and offers a practical route for on-site screening and early intervention in Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.